AstraZeneca, a leading pharmaceutical company, is set to revolutionize lung cancer treatment as it showcases its robust portfolio and pipeline at the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC), scheduled from September 9 to 12, 2023.

‍

Diverse Array of Medicines on Display

With a focus on innovation, AstraZeneca will present over 40 abstracts featuring an impressive lineup of eight approved and potential new medicines. Among these, nine oral presentations and a late-breaking plenary Presidential Symposium presentation will take center stage. Notably, the symposium will unveil results from the FLAURA2 Phase III trial of TAGRISSO® (osimertinib), a potential game-changer for patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) lung cancer.

‍

High Hopes for TAGRISSO® Combination Therapy

AstraZeneca's Executive Vice President of the Oncology Business Unit, Dave Fredrickson, expressed optimism about the groundbreaking results presented at WCLC. He emphasized the company's ambition to cater to more than half of all lung cancer patients with AstraZeneca medicines by 2030. The spotlight will be on the FLAURA2 trial, showcasing promising outcomes from combining TAGRISSO with chemotherapy. This could establish TAGRISSO as a crucial component in the treatment of EGFR-mutated non-small cell lung cancer, an achievement further solidified by its recent Breakthrough Therapy Designation in the US.

‍

ENHERTU and Datopotamab Deruxtecan: Expanding Targeted Options

ENHERTU, AstraZeneca's accelerated approval therapy for previously treated HER2-mutant metastatic lung cancer, continues to demonstrate its potential benefits. Fresh data will be unveiled at WCLC, highlighting its significance for patients in need of targeted solutions. Additionally, the conference will delve into datopotamab deruxtecan, exploring its compatibility with immune checkpoint inhibitors and its role in first-line treatments.

‍

Revolutionizing Treatment Approaches

One of the most anticipated presentations will focus on the FLAURA2 trial's late-breaking plenary Presidential Symposium. This segment will shine a spotlight on the trial's progression-free survival (PFS) data, assessing TAGRISSO's efficacy when combined with chemotherapy for EGFRm non-small cell lung cancer patients in advanced stages. The data revealed a significant improvement in PFS compared to standard-of-care TAGRISSO monotherapy, marking a groundbreaking advancement. Furthermore, TAGRISSO's Breakthrough Therapy Designation in the US underscores its potential in treating advanced EGFRm NSCLC.

‍

Promising Results for Savolitinib and Transformational Technology

Savolitinib, an innovative solution, will also be a highlight, with an oral presentation shedding light on its potential as a first-line treatment for advanced or metastatic NSCLC with MET exon 14 mutations. The drug's approval in China for this indication adds to its credibility.

‍

An e-poster presentation will delve into a computational pathology analysis of MET expression in patients treated with a combination of savolitinib and TAGRISSO. This move showcases AstraZeneca's dedication to developing technology-driven solutions for identifying patients with the highest likelihood of positive treatment response. Encouraging outcomes from this analysis have been previously reported, especially in patients with high levels of MET overexpression and/or amplification whose disease progressed on TAGRISSO treatment.

‍

The upcoming IASLC 2023 WCLC promises to be a watershed moment in lung cancer treatment, with AstraZeneca at the forefront of groundbreaking therapies that hold immense potential to transform patient outcomes. Stay tuned for more updates from this revolutionary event.